Tag: devices

BILLERICA, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- E Ink (8069.TWO), the originator, pioneer, and global commercial leader in ePaper technology, announced the launch of a groundbreaking ePaper touchpad solution for laptops, developed through the integration of Intel^® Smart Base, Intel^® Innovation Platform Framework (Intel^® IPF), and Intel® AI Assistant Builder technologies. This innovative solution combines color ePaper with traditional laptop touchpads, creating a visual, AI-assisted human-machine interface (HMI) that enhances user interaction and brings a whole new dimension of functionality to Intel-based AI PCs.

New Alliance Aims to Scale Grocery Logistics for SMEs With Real-Time Tracking, IoT Integration, and Regional Economic Impact

FREMONT, Calif, July 01, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced that it has entered into definitive agreements for the issuance and sale of 1,626,019 shares of its common stock, Series A-3 warrants to purchase up to an aggregate of 1,626,019 shares of common stock and short-term Series A-4 warrants to purchase up to an aggregate of 3,252,038 shares of common stock, at a purchase price of $0.615 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules.

EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.

Combined Company Expected to be Listed on NASDAQ Global Market